Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease by unknown
Trypanosoma  cruzi trans-Sialidase:  Enhancement  of 
Virulence  in a  Murine  Model  of Chagas' Disease 
By Marina  Chuenkova  and Miercio  E.  A.  Pereira 
From the New England Medical Center, Department of Medicine, Division of Geographic 
Medicine and Infectious Diseases, Boston, Massachusetts 02111 
Summsry 
Trypanosoma cruzi,  the etiological agent of Chagas' disease, expresses a trans-sialidase at highest 
levels in infective trypomastigotes, where it attaches to the plasma membrane by a glycophos- 
phoinositol linkage. Bound enzyme sheds into the extracellular milieu in a soluble form. Experi- 
ments performed in vitro suggest that the trans-sialidase participates in several parameters of 
T. cruzi-host interactions, like cell adhesion and complement resistance.  However, the role that 
membrane-bound and soluble trans-sialidase plays in the infection of mammals is not understood. 
To begin to study the role the enzyme may play in vivo, T. cruzi trypomastigotes were inoculated 
subcutaneously into mice that had been sensitized for various times with the purified protein. 
A single dose of either endogenous or recombinant trans-sialidase injected into the connective 
tissues  of BALB/c mice greatly enhanced parasitemia and mortality. Maximum enhancement 
was achieved with 1-2-h priming. Injection of the enzyme after the parasites had been established 
in the inoculation site had little, if any, consequence in modifying virulence. The enhancement 
did not seem to be through a direct effect of the enzyme on trypomastigote-host cell interactions 
because it occurred when the sites of trans-sialidase sensitization and parasite inoculation were 
physically separate. Rather, virulence enhancement seemed to depend on inflammatory cells, since 
priming with trans-sialidase had no significant effect in severe combined immunodeficiency  mice, 
which lack functional T and B lymphocytes. However, antibody response to T. cruzi in the trans- 
sialidase-primed BALB/c mice was the same as in the control animals.  Virulence enhancement 
was specific for the trans-sialidase because it did not occur in mice primed with Newcastle virus 
sialidase, which has the same substrate specificity as the T. cruzi enzyme, or with the sialidase 
from the bacterium Vibrio cholerae, whose substrate specificity is broader than the trypanosome 
sialidase. Furthermore, no enhancement of virulence occurred after sensitization with another 
adhesion protein (penetrin) purified from T. cruzi trypomastigotes and engineered bacteria, nor 
with bacterial lipopolysaccharide. The virulence-promoting activity of soluble trans-sialidase in 
the mouse model may be physiologically relevant because it was achieved with tiny doses, ,ol-2 
#g/kg, raising the possibility that neutralization of the enzyme with specific probes could impair 
the development of Chagas' disease. In fact, a monoclonal antibody specific for the tandem repeat 
in the trans-sialidase COOH terminus enhanced infection of BALB/c mice, in agreement with 
earlier experiments in vitro, whereas antibodies against an amino acid sequence in the Cys region 
had the opposite effect. 
cruzi causes  Chagas'  disease,  an incurable 
ilitating condition that affects millions of people in 
Latin America (1-3). Acute disease lasts several months, and 
it is characterized by parasitemia caused by rapid intraceUular 
replication of T. cruzi in various tissues  of the host. In con- 
trast,  there is little replication of the parasites  in chronic 
Chagas' disease, which develops several decades after the ini- 
tial infection and is characterized by the megasyndrome, par- 
ticularly cardiomegaly, megaesophagus, and megacolon, which 
generally leads to death. The molecular mechanisms under- 
lying the pathogenesis of Chagas' disease remain unknown. 
T. cruzi expresses a developmentally regulated trans-sialidase 
(4), an enzyme that hydrolyzes sialic acid from glycoconjugates, 
releasing the carbohydrate into water (sialidase or neuramin- 
idase activity) (5) or transferring it to suitable BGal acceptors 
(transferase activity) (6, 7). The sialidase and transferase ac- 
tivities are both specific for sialic acid in ol2,3 linkage (8, 9). 
Therefore, the trans-sialidase produces asialoglycoconjugates 
from sialyl donor substrates, and at the same time generates 
ol2,3-1inked  sialyl derivatives of BGal acceptor substrates. 
The trans-sialidase is located on the surface of infective 
trypomastigotes (10) by a glycophosphoinositol  anchor (11-13), 
and for this reason, it is readily shed into the environment 
whether the parasites are in culture supernatants (14), in the 
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gasic patients (16). Thus, in theory, the trans-sialidase  could 
function in host-parasite interactions either on the surface 
of trypomastigotes or as a soluble mediator (3). 
Surface  membrane trans-sialidase  is believed  to promote 
trypomastigote adhesion by reacting with ot2,3-1inked sialyl 
epitopes present on the plasma membrane of host cells (17-19). 
Consequently, T. cruzi attached to sialic acid-deficient epi- 
thelial cells to a lesser extent than to sialic acid-containing 
parental cells (18-20).  Resialylation of sialic acid-deficient 
cell lines restored T. cruzi attachment to levels similar to those 
of wild-type cells (17, 19). Furthermore, purified trans-sialidase 
at relatively low concentrations (micrograms per milliliter 
range) competitively blocked T. cruzi binding to wild-type 
epithelial host cells (17). The function of the trans-sialidase 
as an adhesion molecule is explained by its low intrinsic siali- 
dase activity (~,2-5% of the sialyltransferase  activity), such 
that in the absence  of/~Gal acceptors,  the enzyme should 
bind to sialoglycoconjugates in a lectin type of action (4, 9). 
The trans-sialidase  may have other roles  in T. cruzi-host 
interactions in addition to mediation of attachment. For ex- 
ample, the enzyme has been postulated to participate in the 
escape  of trypomastigotes from phagolysosomes into  the 
cytosol (13), as well as in the resistance  of trypomastigotes 
to complement activation (4).  Interestingly, when the try- 
pomastigotes exit host cells into the extracellular environ- 
ment, they rapidly acquire sialic acid residues by the catalytic 
action of the trans-sialidase,  which may confer infective prop- 
erties to the parasite  (7). 
These inferences about the role of the trans-sialidase in adhe- 
sion and other parameters of host-T, cruzi interactions were 
all based on assays performed in vitro. To determine the pos- 
sible significance of the trans-sialidase  in an in vivo situation, 
we followed the course of infection of Chagasic mice sensi- 
tized with purified trans-sialidase  and with trans-sialidase  an- 
tibodies before parasite  challenge. BALB/c and C3H mice 
primed with extremely low amounts of the trans-sialidase 
('~20-30 ng per mouse) became remarkably sensitive hosts 
for T. cruzi growth. In fact, it was possible  to turn a non- 
lethal dose of T. cruzi into a mortal inoculum by sensitizing 
connective tissues of mice with picomole amounts of the en- 
zyme. A monoclonal antibody reactive with the tandem re- 
peat in the COOH-terminal domain of the trans-sialidase  en- 
hanced virulence, whereas antibodies against a peptide in the 
NH2 terminus were protective. The molecular basis for this 
virulence-enhancing effect of the trans-sialidase  remains to be 
determined, but it appears to depend on functional nonim- 
mune host lymphocytes. 
Materials  and Methods 
Parasites.  All studies were performed with the cloned Silvio 
X-10/4 and MV-13 strains of T. cruzi used in earlier studies (14, 
20), as well as with Tulahuen clone C2 provided by Dr. Steve Reed 
(Infectious Diseases Institute, Seattle, WA) (21). Trypomastigotes 
were propagated in Vero cells as previously described (14, 20). 
Antibodies.  mAb  TCN-2  (IgG1) was  isolated from  a C3H 
mouse chronically infected with a clone of MV-13 that expresses 
high trans-sialidase activity (20). The antibody was purified from 
hybridoma supernatants on protein G-Sepharose columns (Phar- 
macia Fine Chemicals, Piscataway,  NJ) equilibrated with PBS, pH 
7.5; bound antibodies were eluted with 0.1 M glycine-HC1  buffer, 
pH 2.5, and immediately dialyzed against PBS. Isotype-matched 
control antibody was a hybridoma  against  p-azophenylarsonate  (20), 
which was also purified on protein G-Sepharose as above. Fab frag- 
ments of the antibodies were obtained by digestion with papain 
as described (22). Sizes  of Fah fragments were confirmed  by sieving 
chromatography on Sephadex  G-100 and by the absence of  binding 
to protein G-Sepharose. 
Antibodies to peptide C (RLPKRMGGSYRC, ref. 12) were 
elicited in BALB/c  or C3H mice by intraperitoneal injection of 100 
/zg of the synthetic peptide (without a protein carrier) in the pres- 
ence of  complete Freund's adjuvant, followed  by three to five  injec- 
tions of the same amount of the synthetic peptide in incomplete 
Freund's adjuvant every 7-10 d. Anti-peptide C IgG was purified 
on protein G-Sepharose, and the IgG fraction specific  for the syn- 
thetic peptide was isolated on an affanity  adsorbent prepared by 
coupling peptide C to Sepharose 4B by activation with cyanogen 
bromide ("3-5 mg peptide/ml settled beads). IgG ('~5 mg) bound 
to the peptide C-Sepharose column was specifically  eluted by addi- 
tion of soluble synthetic peptide (2 mg/ml) to the equilibrating 
PBS buffer (yield of anti-peptide C IgG, ~2.3 mg). Peptide C was 
separated from the antibody by extensive  dialysis.  Anti-peptide C 
antibody was also purified from Chagasic sera, which consisted 
of a pool of sera with indeterminate and chronic Chagas' disease 
from the endemic area of Bahia, Brazil. These sera are the same 
pool used in previous studies (14, 23) and were originally prepared 
by Dr. Rodney Hoff  (National Institutes of  Health, Bethesda, MD). 
Peptide C antibodies were purified from Chagasic sera by the same 
procedure used to isolate mouse anti-peptide  antibody. 
Purification of trans~Sialidase and Penetrin.  T cruzi trans-sialidase 
was purified as previously described (9). Briefly, conditioned su- 
pernatants of Veto cell cultures infected  with T. cruzi Silvio-X10/4, 
MV-13, or Tulahuen, were applied to at~nity columns of mAb 
TCN-2 adsorbed to protein G-Sepharose; trans-sialidase bound to 
insolubilized TCN-2 was eluted with synthetic peptide TR (DSS- 
AHGTPSTPA, 10 mg/ml) and separated from the synthetic pep- 
tide by fast protein liquid chromatography  on a Superose 12 column 
equilibrated with PBS. The purified protein migrated as a 200-kD 
doublet  as assessed by SDS-PAGE and silver staining (9). The 
recovery of the isolated enzyme ranged from 5-10/zg/100  ml of 
conditioned medium, trans-Sialidase purified from the Y strain of 
T. cruzi involved  Con A a~nity binding, sizing, and ion-exchange 
chromatography (24) and was a gift from Drs. Lain de Carvalho 
and Victor Nussenzweig (New York University, New York, NY). 
Water used in  the  trans-sialidase purification was sterile and 
pyrogen free (Abbott Laboratories,  Abbot Park, IL). The LPS con- 
tent of some trans-sialidase preparations was quantitated by the 
Limulus amebocyte assay following the recommendations of the 
manufacturer (Associates of Cape Cod Inc., Woods Hole, MA), 
and it was found to be below the detection limit of the assay. 
Recombinant trans-siaF,  dase was purified using the same protocol 
as for the endogenous  enzyme.  Escherichia coli XL-1 blue transformed 
with Bluescript plasmid containing trans-sialidase inserts (7F, 19Y, 
and 17D) were grown and harvested as previously described (12). 
The trans-sialidase gene in these inserts is on the T7 side of the 
Bluescript plasmid and is not induced by isopropylthioglycoside. 
Instead, the trans-sialidase protein is expressed constitutively in the 
cytosol of these bacteria in a soluble form. The yield of affmity- 
purified recombinant protein ranged from 5 to 50 mg/liter of bac- 
terial culture. Large batches of  bacteria were grown in the GRASP 
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Penetrin was isolated from T. cruzi trypomastigotes and E. coli 
HBP-6 by heparin-Sepharose chromatography as previously de- 
scribed (25). 
Immunoblots.  SDS-PAGE  and immunoblots oflysates ("o10 #g 
per lane) and purified proteins (0.5 #g per lane) were performed 
as previously described (20). 
Protein Determination.  trans-Sialidase  concentration  was estimated 
by SDS-PAGE. A standard curve was set up by applying various 
amounts (0.005-0.1 #g per lane) of BSA on a 7.5% SDS-poly- 
acrylamide gel. Proteins in the gel were stained with silver or pro- 
blue (Integrated Separation Systems, Hyde Park, MA) and quanti- 
tated in a laser-scanning densitometer (LKB Instruments,  Inc., 
Gaithersburg, MD). Various volumes of the purified trans-sialidase 
solution were applied to the SDS-polyacrylamide gel in parallel 
with BSA, and the concentration of the enzyme was estimated by 
comparison with the BSA standard curve. 
Penetrin was estimated by the Bradford procedure following the 
recommendations  of  the manufacturer  (Bio-Rad  Laboratories,  Rich- 
mond, CA). 
trans-Sialidase Assay.  The trans-sialidase assay  was performed as 
described (9). Enzyme in 10 #1 was added to 40 #1 of 50 mM PBS, 
pH 7.2, containing 0.5 mmol of 2,3-sialyllactose  (Sigma Chemical 
Co., St. Louis, mo), 0.25 mmol of [14C]N-acetyllactosamine  (4 
x  10  s dpm), 50/zg BSA, and 0.02% NAN3. After incubation for 
various times at room temperature, the reaction mixture was diluted 
to 1.0 ml with distilled water and applied to a column containing 
1.0 ml Q-Sepharose equilibrated  with water. Sialylated  product was 
eluted with 1 M NaC1 and quantitated by scintillation counting. 
ELISA.  ELISA  was a modification of a procedure described 
earlier (26). In brief, polyvinyl microtiter plates (Coming Glass 
Inc., Coming, NY) were coated  overnight  at 4~  with ~100/xg/ml 
of T. cruzi antigens prepared by lysing trypomastigotes (10S/ml) 
with the detergent 3-([3-cholamidopropyl]-dimethylammonio)-l- 
propane-sulfonate (0.1%) containing protease inhibitors (5 mM 
EDTA, 5 mM iodoacetamide, 5 #g/ml each leupeptin, pepstatin, 
and soybean trypsin inhibitor).  Plates were washed twice with 
PBS-0.05% Tween 20 and blocked with 1% heat-treated (56~ 
30 rain) BSA (room temperature for 1 h), followed by addition 
of various dilutions of sera of infected  and control noninfected  mice. 
After 1 h at room temperature, plates were washed three times 
with PBS-Tween 20, incubated for 1 h with an alkaline phospha- 
tase-labeled goat anti-mouse antibody (Promega Corp., Madison, 
WI), and after washing, bound antibody was detected with the 
substrate p-nitrophenyl phosphate (1 mg/ml) in diethanolamine 
buffer (pH 9.8). Reaction was stopped after 1 h with 3 M NaOH 
and the absorbance measured at 405 nm using an automated ELISA 
reader (Bio-Tek Instruments Inc., Winooski, VT). 
Chagasic Mouse Model.  Female  BALB/c  and C3H mice (Taconic 
Farms Inc., Germantown, NY), 8-10 wk old, were injected sub- 
cutaneously into the footpads with 12 #1 of sterile, pyrogen-free 
PBS (in tuberculin syringes) without (control) or with purified 
trans-sialidase (1-5 #g/ml), Newcastle virus sialidase (10 mU/ml) 
(Genzyme Corp., Cambridge, MA),  Vibrio cholerae sialidase (10 
mU/ml)  (Calbiochem Corp.,  La Jolla,  CA),  penetrin  (10-100 
/xg/ml), and E. coli LPS (10 #g/m1) (serotype N0127:B8; Sigma 
Chemical Co.). After various times, 12 #1 of a trypomastigote sus- 
pension of the Tulahuen  strain (0.2-2  x  105/ml), freshly  harvested 
from Veto cell monolayers, was inoculated into the footpad that 
had been primed with the trans-sialidase, or the other footpad, or 
the peritoneal cavity. In some experiments, trans-sialidase priming 
and parasite inoculation were both done in the two footpads (see 
Table 1); in this case, the injection consisted of 25 #1 (12.5/xl per 
footpad) of priming solution and parasite suspension. In some ex- 
periments, parasites were inoculated  in the soft tissue first, followed 
at different  time intervals  by trans-sia~,dase. Mice  were removed  from 
the study if extensive  bleeding occurred after the subcutaneous in- 
jection. 
Mice were bled in the tail at various times after inoculation, 
and bloodstream trypomastigotes  were quantitated  by two methods: 
(a) counting in a hemocytometer under a light microscope, as de- 
scribed by Brener (27), and (b) PCR of the blood parasites using 
a highly sensitive probe, as described  by Moser et al. (28). Results 
given in the various figures described below were obtained with 
the first method described above. 
Results 
Virulence-promoting Activity of the T. cruzi trans-Sialidas~  One 
of the pathways used by T. cruzi to attach to cultured mam- 
malian cells depends on host cell receptors  containing ot2,3- 
linked sialic acid epitopes (3, 17). In an attempt to test whether 
T. cruzi uses sialyl residue receptors  during invasion in vivo, 
we primed the footpads of BALB/c mice with small amounts 
of the purifed T. cruzi trans-sialidase. By analogy with results 
obtained in vitro (17), the expectation was that priming soft 
tissues with the purified trans-sialidase, followed by a T. cruzi 
inoculum, would reduce parasite  invasion as measured by 
parasitemia  and survival  of the mouse host. 
But contrary to expectation,  mice sensitized with the trans- 
sialidase exhibited high parasitemia  and died early compared 
with control mice, which were treated in the same way as 
the experimental mice, except that priming of the tissues was 
with vehicle medium without the sialidase. In fact, using 
an  inoculum  of trypomastigotes  that  produces  transient 
parasitemia, it was possible to turn a nonlethal dose of T. cruzi 
into a mortal one by priming soft tissues of mice with a single 
amount of enzyme as small as 20 ng per mouse (Fig.  1, A 
and C). This enhancement of virulence was obtained with 
trans-sialidase  isolated from the Tulahuen strain of T. cruzi. 
trans-SialJdase purified from another strain of the parasite, Silvio 
X-10/4,  likewise enhanced T. cruzi virulence (see below). 
In addition to the Tulahuen and Silvio X-10/4 trans-sialidases 
isolated in our laboratory, we tested Y strain trans-sialidase 
purified in a different laboratory (24) by a protocol distinct 
from ours (see Materials and Methods). The Y strain enzyme, 
as did the other trans-sialidases, potently enhanced parasitemia 
and mortality of BALB/c mice (Fig. 1, B and D, respectively). 
The virulence-promoting activity of the trans-sialidase was 
not confined to BALB/c mice (H-2 a haplotype) since the en- 
zyme also enhanced parasitemia and mortality of C3H mice 
infected with T. cruzi (H-2  k haplotype) (data  not shown). 
Virulence-promoting Activity by Recombinant trans-Sialidase. 
The trans-sialidase used in the experiments described above 
was isolated from conditioned media of monolayers infected 
with T. cruzi. Although the T. cruzi enzyme was homogene- 
ously pure, the possibility existed that the virulence-promoting 
activity of the preparations was caused by contaminants de- 
rived from fetal calf sera and/or from secretory products of 
the fibroblast monolayers. To discard this possibility, we used 
recombinant trans-sialidase purified from bacteria transformed 
with plasmids 7F, 19Y, and 17D, which contain the trans- 
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Figure  1.  Enhancement of T cruzi virulence for BALB/c mice sensi- 
tized with the trans-sialidases. Groups of four mice were sensitized in the 
soft tissue of their footpads with "~20 ng of trans-fialidase purified from 
Tulahuen (A and C) and Y (/3 and D) strains of T. cmzi. After one 1 h, 
the mice were inoculated in the sensitization site with 103 trypomastigotes 
of the Tulahuen (~/a) strain. Blood was collected from tail vessels, and 
bloodstream trypomastigotes were counted in a hemocytometer. Control 
represents mice primed with vehicle medium. 
sialidase gene (12). Recombinant trans-sialidase was purified 
using the same type of immunoaf~nity adsorbent and eluant 
that is used for purification of the endogenous enzyme (9). 
Specifically,  bacterial lysates containing  recombinant  trans- 
sialidase were adsorbed to insolubilized mAb TCN-2, which 
reacts with the COOH-terminal  tandem repeat of the en- 
zyme (29). Recombinant enzyme bound to the column was 
desorbed with  synthetic peptide TR (DSSAHGTPSTPA), 
a TCN-2 hapten (29).  Specific trans-sialidase activity of the 
recombinant bacterial proteins was 12-42% that of the en- 
dogenous trypomastigote enzyme (Fig. 2 A). By SDS-PAGE, 
recombinant  trans-sialidase migrated as bands of ,x,200 kD 
as determined by staining with silver or pro-blue (Fig.  2 B). 
Recombinant trans-sialidases  such as 17D, at 30 ng per mouse, 
significantly increased parasitemia and reduced survival of the 
Chagasic animals, similar to the effect of the trypomastigote 
enzyme (Fig.  2,  C  and D). 
Specificity  of the  Virulence-enhancing  Activity  of the  trans- 
Sialidase.  Using a protocol similar to that described in Figs. 
1 and 2, footpads of BALB/c mice were primed with viral 
and bacterial sialidases  followed by an inoculum of T. cruzi 
trypomastigotes I h later. The viral enzyme was from New- 
castle disease virus  (NCV) 1 because this  enzyme,  like the 
T. cruzi trans-sialidase,  hydrolyzes sialic acid-linked c~2,3 but 
not a2,6 (30). The effect of the NCV sialidase was the oppo- 
site of that produced by the trans-sialidase.  Thus, NCV siali- 
dase-primed mice developed somewhat lower parasitemia (Fig. 
3 A) and died slightly later (Fig.  3 B) than control mice, 
which were treated in the same way as the experimental mice, 
except that priming of the tissues was with vehicle medium 
without  sialidase.  Similarly,  sialidase  from  the  bacterium 
V. cholerae, which hydrolyzes sialic acid-linked c~2,3 and c~2,6, 
slightly reduced parasitemia and survival of the infected mice 
(data not shown), in agreement with results using culture 
cells  (17,  31).  These results suggest  that  the virulence-en- 
hancing effect of the trans-sialidase was restricted to the T. cruzi 
enzyme. 
The  specificity of the  trans-sialidase  action  was further 
demonstrated  with  penetrin,  which  is  a  T. cruzi  heparin- 
binding protein that promotes trypomastigote adhesion to 
and invasion of mammalian  cells in vitro (25).  Unlike the 
trans-sialidase,  priming of BALB/c mice footpads with pene- 
trin, isolated either from trypomastigotes or from engineered 
bacteria, did not significantly alter the course of T. cruzi in- 
fection (Table  1) 
Because LPS is a potent stimulator of immune responses, 
in particular of B lymphocytes (32), a trivial explanation for 
the virulence-enhancing effect of the trans-sialidase  might be 
attributed to LPS contaminating  the trans-sialidase  prepara- 
tions. We purified the trans-siahdase using pyrogen-free water 
and reagents,  such that enzyme preparations had undetect- 
able levels of LPS (<100 pg LPS/#g trans-sialidase)  as assessed 
by the Limulus amebocyte assay. Furthermore, priming foot- 
pads of BALB/c mice with purified bacterial LPS for I h did 
not alter parasitemia,  contrary to the effect of the trans-sialidase 
(Table  1). 
Kinetics  of  the  Virulence-promoting  Activity  of  the  trans- 
Sialidase.  Sensitization of mouse soft tissues with the trans- 
sialidase (20 ng per mouse) for various times followed by in- 
oculation of trypomastigotes into the priming  site revealed 
that the enzyme enhanced virulence optimally after 1 h  of 
sensitization (Fig.  4, A  and B). Priming the mice with the 
trans-sialidase  for as long as 24 h still produced a noticeable 
effect, as did injection of the enzyme together with the para- 
sites (Fig.  4, A  and B). Interestingly, injection of the trans- 
sialidase I>1 h after the T. cruzi inoculum had no noticeable 
effect on the course of infection  (Fig.  4, A  and B). 
The trans-Sialidase Enhanced Infection  Whether It Sensitized 
the T. cruzi Inoculation  Site or a Distinct Site.  We considered 
the possibility that trans-sialidase priming enhanced parasitemia 
by promoting migration of trypomastigotes inoculated into 
the soft tissues of the mouse, which would have greater access 
to neighboring host cells and blood vessels. Thus, if this were 
the case, we should find increased parasitemia of the inocu- 
lated parasites before their invasion and replication inside host 
1  Abbreviations used in this paper: NCV, Newcastle disease virus; SCID, 
severe combined immunodeficiency. 
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Figure 2.  Characteristics  of recombinant  tmns-sialidase.  (A) Specific  trans- 
sialidase activity of purified recombinant (7F, 19Y, 17D) and endogenous 
(TS, Tulahuen)  trans-sialidases.  (B ) Pro-blue  staining of  SDS-polyacrylamide 
gel (7.5%) run with lysate orE. coli transformed with trans-sialidase  gene 
(clone  7F; lane  I ) and recombinant  trans-sialidase  7F purified  on mAb TCN-2 
affinity  column (lane  2). Lane  3 represents  immunoblot of  purified  7F probed 
with the trans-sialidase  mAb TCN-2. (C) Parasitemia and (D) Survival 
of mice primed in the footpads for t h with 25 ng of endogenous (TS, 
Tulahuen) and recombinant (171))  trans-sialidases. Similar  results were ob- 
tained with 7F and 19Y recombinant trans-sialidases. 
cells at the inoculation site. However, no such increase in early 
parasitemia was detected when bloodstream trypomastigotes 
were quantitated by various criteria, including light micros- 
copy and PCR using a highly sensitive probe (28) (data not 
shown). Parasitemia augmented by trans-sialidase priming was 
observed only ~2 wk after inoculation, when the infection 
was presumably amplified by several cycles of trypomastigote 
invasion  of cells in peripheral  tissues. 
On the other hand, exacerbation of infection was observed 
regardless of whether the parasites were inoculated into the 
site primed  with  the trans-sialidase  (same footpad)  or into 
a site distinct (different footpads as shown in Fig. 5 or footpad 
and intraperitoneal cavity, data not shown) from the priming 
site.  The result shown  in Fig.  5  suggests  that alteration of 
host  responses  to  T. cruzi  infection is  one possible mecha- 
nism for the virulence-enhancing activity of the trans-sialidase. 
The trans-Sialidase Did Not Enhance Virulence  in Severe Com- 
bined Immunodeficiency (SCID) Mice,  SCID mice are devoid 
of functional T  and B lymphocytes while having functional 
macrophages and NK ceils (33). To determine whether the 
virulence-enhancing activity of the trans-sialidase  was depen- 
dent on functional lymphocytes, we followed the course of 
infection of SCID  mice that  had  been  sensitized with  the 
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i 
0  10  2{)  ~0 
MWr Inoculation 
Figure 3.  Effect  ofNCV sialidase 
in the course of T, cruzi infection in 
BALB/c  mice.  Protocol  similar  to that 
of Fig. 1, e~cept  priming of the soft 
tissues (footpad)  was with NCV siali- 
dase (20 U  '~10 #g protein) 
trans-sialidase (25 ng per mouse,  1-h priming).  Parasitemia 
in the trans-sialidase-sensitized  SCID mice was not significantly 
different from control mice (Fig. 6), unlike the findings with 
immune competent mice (Fig. 1). Furthermore, the mortality 
curve for the trans-sialidase-primed  mice was the same as for 
the control mice (data not shown). These results suggest that 
the virulence-promoting activity of the trans-sialidase  requires 
functional lymphocytes of the host. 
Table  1.  Parasitemia of T.  cruzi-infected BALB/c  Mice 
Sensitized  with a Single  Dose of trans-Sialidase, Penetrin, and LPS 
Trypomastigotes/ml 
blood  x  10  s at day 
Mice  sensitized  with  11  15 
PBS (control)  10  +  4  62  +  20 
TS (Silvio X  10/4)  18  +_  6  328  +_  60 
Penetrin  16  _+  3  52  +  12 
Bacterial  LPS  11  +  1  67  +  21 
Groups of three BALB/c mice were primed in the two footpads with 
25 #1 of PBS (control), purified trans-sialidase  (TS) of Silvio X-10/4 (1 
#g/ml), recombinant  penetrin (100  #g/ml), and bacterial  LPS (10 #g/ml). 
After I h, 25 #1 of tissue culture trypomastigotes (Tulahuen strain, 2  x 
10S/ml) were inoculated in the priming site. Mice were bled in their tail 
and bloodstream trypomastigotes counted in a hemocytometer on the 
indicated days. Lower concentrations of penetrin (10 #g/ml) and LPS 
(1 #g/ml) gave similar results to those shown above. 
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Figure 4.  Kinetics  of the trans- sialidase-induced  enhancement  of viru- 
lence. BALB/c  mice were primed with the endogenous  (Tulahuen) trans- 
sialidase (30 ng/mouse)  for the indicated  times  and inoculated  with 2 x 
103 trypomastigotes.  Control  represents mice primed for I h with vehicle 
medium. Parasitemia (A) and survival (B) are displayed  for the 16th d 
after inoculation. 
trans-Sialidase Priming Did Not Boost Antibody Response  to 
T. cruzi.  One explanation for the enhancement of T. cruzi 
growth in BALB/c mice is that enzyme priming would lower 
humoral and cell-mediated immunity to the parasite during 
the course of infection. To test if antibody response to T. cruzi 
was altered by trans-sialidase priming, we measured by ELISA 
the antibody titers against T. cruzi in the sera of primed and 
nonprimed control BALB/c mice infected with Tulahuen 
trypomastigotes. As  shown in Fig.  7,  titers of antibodies 
against T. cruzi trypomastigotes were not affected by trans- 
sialidase priming, in contrast to the parasitemia in primed 
and control animals.  Thus, at least  in BALB/c mice, trans- 
sialidase-induced enhancement of virulence cannot be attrib- 
uted to reduced antibody response  to  T. cruzi. 
~ 
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Figure 5.  7~ans-sialidase  enhances  virulence  where  priming and inocu- 
lation sites are physically  apart. BALB/c mice were primed with endoge- 
nous trans-sialidase and inoculated  with trypomastigotes 1 h later in the 
priming site (same footpad) or in a distinct site (the other footpad). 
Parasitemia  at day  20 (A) and survival  (%) at days  20 and 25 (B) are displayed. 
Effect  of trans-Sialidase Antibodies on the Course of T. cruzi 
Infection in BALB/c Mice.  Earlier studies showed that poly- 
clonal and monoclonal trans-sialidase  antibodies enhanced 
T. cruzi infection of fibroblasts  and smooth muscle cells in 
vitro (14, 20).  One of the enhancing mAbs, TCN-2,  was 
specific for the tandem repeat in the COOH terminus of the 
trans-sialidase (29). To test whether these antibodies were also 
active in vivo,  BALB/c mice were inoculated with T. cruzi 
in the presence of 24.5/zg of  protein G-purified mAb TCN-2. 
Remarkably, administration of  TCN-2 greatly enhanced para- 
sitemia and mortality compared with control mice that re- 
ceived isotype-matched IgG instead of TCN-2 (Fig. 8, A and 
B). The monovalent Fab fragment of TCN-2 (18.8/~g per 
mouse) also increased T. cmzi virulence (Fig. 8 A), suggesting 
that the effect of TCN-2 was not caused by Fc-mediated en- 
docytosis of the parasite  by macrophages and other cells. 
We also studied the effect of antibodies against the Cys- 
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Figure  6.  Effect of trans-sialidase 
priming in SCID mice infected with 
T. cruzi.  Protocol similar to that of 
Fig.  1 except the parasite inoculum 
was 200, instead of 1,000  trypomas- 
tigotes. 
rich part of the trans-sialidase  in vivo. Most experiments were 
done with antibodies against peptide C (3SlRLPKRMGGS- 
YRC  392, numbering from the recombinant trans-sialidase  7E 
ref.  12). Two types of peptide C antibodies were used: anti- 
bodies raised in mice by immunization  with  the synthetic 
peptide in the presence of Freunds' adjuvant, and antibodies 
from mouse or human  Chagasic sera.  Affinity purification 
of the antibodies was by adsorption  to peptide C  coupled 
to Sepharose beads and specific elution with soluble synthetic 
peptide C. The affinity-purified  peptide C antibodies inhibited 
trans-sialidase activity and depleted enzyme from trypomas- 
tigote lysates after adsorption to protein G-Sepharose (Ming, 
M.,  and M.  E.  A.  Pereira,  manuscript  in preparation). 
All types of peptide C  antibodies  aborted the course of 
T. cruzi infection in BALB/c mice, although  the peptide C 
antibodies isolated from human Chagasic sera were the most 
potent. A concentration as low as 9.6 #g of the human anti- 
body per mouse dramatically reduced parasitemia to barely 
detectable levels (Fig. 8 B), and it completely protected mice 
from the lethal inoculum of T. cruzi (Fig.  8 D). In addition, 
peptide C antibodies were also very active in abrogating T. cruzi 
infection in vitro (Ming, M., and M. E. A. Pereira,  manu- 
script in preparation).  Interestingly,  vaccination with pep- 
tide C  reversed the virulence of T. cruzi for BALB/c mice 
(Ming, M., and M. E. A. Pereira, manuscript in preparation). 
The results with  the trans-sialidase  antibodies further  sup- 
port the inference that  the enzyme is a virulence factor in 
Chagas'  disease. 
Discussion 
We show here that sensitization of mice with T. cruzi trans- 
sialidase followed by an inoculum of Tulahuen trypomastigotes 
in the priming site or in a distinct site significantly enhanced 
parasitemia and mortality of the infected animals.  Both en- 
dogenous and recombinant  enzyme were effective in aug- 
menting virulence.  The enhancement was specific because viral 
and bacterial sialidases were inactive, as was penetrin (Table 
1), a heparin-binding  protein of T. cruzi that,  as the trans- 
sialidase,  promotes trypomastigote attachment  to host cells 
(25). In another system, the V. cholerae sialidase was reported 
to promote intracellular killing, rather than survival, of mi- 
crobes in vivo (34). 
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Figure  7.  trans-sialidase  priming did not alter titers of antibodies to 
T. cruzi in Chagasic mice. BALB/c mice were primed with vehicle medium 
(control) and trans-sialidase  as in Fig. 1. At the indicated days, parasitemia 
was determined by light microscopy and antibody elicited to trypomastigotes 
estimated by ELISA. --[3-, control; -I-,  TS. 
The trans-sialidase is anchored to the plasma membrane of 
trypomastigotes by a glycophosphoinositol anchor (11), and 
consequent to the action of endogenous and environmental 
phospholipases,  the enzyme is readily shed in the environ- 
ment inhabited by the trypanosomes, including tissues of mice 
(3) and humans (16) infected with T. cruzi. Therefore, soluble 
enzyme released in vivo during infection of mammals might 
exert an effect analogous to the one reported here. Quantita- 
tive considerations further suggest that the enhancement of 
virulence in the mouse model is of physiological significance, "'O'- 
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Figure  8.  Effect of passive administration of trans-sialidase antibodies 
on the course of T cruz/infection. Tulahuen trypomastigotes were incubated 
with the indicated antibodies for 1 h at room temperature and inoculated 
subcutaneously into  the  footpad  of  BALB/c  mice.  Anti-Ars,  anti-p- 
nitrophenylarsonate. 
as it was achieved with very small amounts of enzyme, ~1-5 
/~g/kg  or  low picomole range per  kilogram.  Such small 
amounts of trans-sialidase  could be shed by T. cruzi in the 
acute phase of Chagas' disease, where parasites are abundant 
in peripheral tissues and in the circulation (1,  2). 
One  explanation  for  enhanced parasite  thriving in  the 
primed mice relates to a direct interference of the trans-sialidase 
in T. cruzi-host cell associations,  similar to the enzyme effect 
in vitro (17). However, direct interference is an unlikely ex- 
planation  because  virulence was  enhanced when  enzyme 
priming and parasite inoculation sites were physically distinct 
from one another, such as in different footpads or a footpad 
and intraperitoneal cavity (Fig.  5). Kinetic data (Fig. 4) are 
also inconsistent with such a mechanism, for enhancement 
was  optimum  after trans-sialidase  priming  for  1-2  h  and 
negligible when the enzyme was injected after the parasites. 
In addition, the amount of enzyme needed to induce viru- 
lence (~20-30 ng per mouse) seemed to be too small to effec- 
tively diffuse through the tissues and directly interfere with 
T. cruzi binding to host cells. Instead, the results are consis- 
tent with  the trans-sialidase  indirectly stimulating parasite 
growth in vivo. This would occur if the trans-sialidase would 
bind to receptors on cells of the immune system and trigger 
a cascade type of reaction, resulting in reduced host response 
against the parasite. 
Host cells that might indirectly promote invasion are those 
that participate in the inflammatory response, such as leuko- 
cytes and macrophages. These cells become activated after 
reaction of surface receptors with specific ligands in the ex- 
tracellular environment. Many surface receptors are sialylated 
glycoproteins, which send signal-transdudng signals not only 
after engagement with specific ligands, but also after reac- 
tion with the plant lectins Con A  and PHA.  Because the 
trans-sialidase is a sialic acid-binding protein, it could acti- 
vate inflammatory cells by binding to sialic acid in the carbo- 
hydrate side chains of a given receptor. 
One candidate receptor is CD45, which is the most abun- 
dant glycoprotein on leukocytes, where it comprises ~10% 
of the T  lymphocyte surface (35,  36).  It is a member of a 
novel class of enzymes, named protein tyrosine phosphatase, 
and as such, CD45 is linked to reversible  protein tyrosine 
phosphorylation (37). Tyrosine phosphorylation is a key regula- 
tory mechanism controlling growth and division of eukary- 
otic cells (38). The extracellular domain of CD45 is heavily 
glycosylated, bearing many N- and O-linked carbohydrates 
containing c~2,3-1inked sialic acid (35, 36), precisely the struc- 
tures recognized by the trans-sialidase  (8,  9).  Interestingly, 
CD45 carbohydrates on T lymphocytes interact with the plant 
lectin PHA, inducing T cells to enter the S phase of the cell 
cycle (39). 
It is not unreasonable to think that the trans-sialidase will 
bind to inflammatory cell receptors, since it reacts with sialic 
acid on the surface of erythrocytes and endothelial cells (40, 
41),  on soluble glycoproteins such as orosomucoid and fe- 
tuin (5),  and on oligosaccharides (8, 9). However, only ex- 
periments will tell whether trans-sialidase binding to inflam- 
matory cells will lead to their activation or deactivation. It 
is of interest to note that purified trans-sialidase  stimulates 
DNA synthesis (i.e.,  [3H]thymidine incorporation) in cul- 
tures of nylon wool-purified na'fve lymphocytes of mouse and 
human origin (Ming, M., and M. E. A. Pereira, unpublished 
observations). Consistent with this hypothesis, trans-sialidase 
sensitization followed by T. cruzi infection of SCID mice that 
lack functional B and T lymphocytes (33) failed to enhance 
parasitemia and mortality (Fig. 6). These results are in agree- 
ment with the hypothesis that the trans-sialidase enhanced 
virulence in the animal model by altering immune responses 
critical to combat invasion of T. cruzi and perhaps of other 
parasites.  However, trans-sialidase priming did not suppress 
or enhance antibody response to the trypanosomes in the Cha- 
gasic mice (Fig.  7), suggesting that virulence enhancement 
was not caused by an alteration in the amount of antibody 
produced against the parasite.  We do not know yet if the 
priming altered cell-mediated immunity to T. cruzi. In an- 
other system, the V. cholerae sialidase was reported to enhance 
antibody response in vivo to various antigens (42). 
It is implicit in this hypothesis that the virulence-enhancing 
effect is mediated by the sialic acid-binding site of the trans- 
sialidase. However, because the trans-sialidase is a multido- 
main protein (12), it is not inconceivable that the enzyme 
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catalytic region. One such site is the fibronectin type III do- 
main,  which is present  not only in the trans-sialidase, but 
also in other trans-sialidase family members (4). Fibronectin 
type III domains of fibronectin and other adhesion proteins 
participate in various types of protein-protein interactions 
(43), and by analogy, the trans-sialidase unit might have a 
similar role. 
The trans-sialidase may behave like other microbial adhe- 
sive proteins that, on one hand, directly participate in host- 
parasite interactions, and on the other hand, indirectly con- 
tribute  to  the  infective  process by  altering  physiological 
parameters of the mammalian host. One example of such pro- 
teins is the coat gp120 of HIV, which recognizes  CD4 receptor 
molecules on T lymphocytes during viral adherence and entry 
(44). In addition, gpl20 triggers important biological activi- 
ties thought to be related to the pathology of HIV infection. 
Soluble gp120 reacts with monocytes, inducing the release 
of cytokines  and arachidonic  acid metabolites, which may affect 
the function of immunocompetent cells (45), and it kills cor- 
tical neurons  at low picomolar concentrations  by stimula- 
tion of nitric oxide and superoxide anions, an activity that 
could be related to AIDS dementia (46). Another example 
is HIV Tat protein,  which stimulates viral gene expression 
by binding to specific promoters (47). In addition,  Tat has 
profound effects on mammalian ceils such as induction of 
proliferation  and TGF-B expression in chondrocytes  (48). 
The effect of passive administration  of trans-sialidase anti- 
bodies in vivo are of interest. The enhancement of infection 
produced by mAb TCN-2 is consistent with early findings 
in vitro, which showed this antibody, as well as rabbit poly- 
clonal antibodies, to increase T. cruzi binding and invasion 
of mammalian cells in culture (14, 20). This enhancement 
may not result from facilitation of Fc-mediated endocytosis 
of the parasite, because  the monovalent Fab fragment of  TCN-2 
was as active as the bivalent IgG (Fig. 7 A). The remarkable 
effect of TCN-2 in vivo may perhaps be related to the fact 
that the antibody was obtained from the spleen of a mouse 
chronically  infected  with T. cruzi and not artificially  immunized 
with the enzyme (20). Consequently,  tandem repeat anti- 
bodies could have a similar effect  in Chagasic individuals. Most 
patients with acute Chagas' disease  develop antibodies against 
the trans-sialidase tandem repeat (49), and it is not inconceiv- 
able that tandem repeat antibodies  found in natural infec- 
tions could have a positive effect in parasite growth in the 
mammalian host. 
But not aU antibodies enhanced  infection. Antibodies against 
an amino acid sequence (peptide C) present in the Cys-rich 
region of the trans-sialidase was remarkably potent in reducing 
infection when administered subcutaneously with the para- 
sites. Most active were those peptide C antibodies isolated 
from a pool of sera of patients with indeterminate and chronic 
Chagas'  disease. Thus, antibodies  against various domains 
of the trans-sialidase elicited in vivo during natural infections 
may influence parasitism in opposite ways. This would not 
be unique,  since antibodies against the lectin of Entamoeba 
histolytica had an effect similar to the trans-sialidase antibodies 
in that they either enhanced or blocked lectin-mediated cy- 
tolysis of cultured epithelial cells (50). 
In conclusion, the results presented here show that priming 
soft tissues with trans-sialidase enhances T. cruzi infection in 
mice. We hypothesize that the enhancement results from the 
activation/deactivation  of host inflammatory cell responses. 
We propose that when T. cruzi infects a mammalian host, 
the trypomastigote-bound trans-sialidase binds to sialyl  residues 
on the surface of fibroblasts and other host cells as a prelude 
to attachment and penetration. At the same time, trans-sialidase 
released by trypomastigotes into the environment binds to 
receptors (most likely o~2,3-sialyl epitopes) and modifies host 
functions  such  as  those of inflammatory cells, ultimately 
resulting in enhanced invasion. This model is consistent with 
the augmentation and diminution of infection in vivo by trans- 
sialidase antibodies. 
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